Adalimumab biosimilar - Momenta Pharmaceuticals

Drug Profile

Adalimumab biosimilar - Momenta Pharmaceuticals

Alternative Names: BAX 2923; M 923

Latest Information Update: 15 Feb 2017

Price : $50

At a glance

  • Originator Momenta Pharmaceuticals
  • Developer Momenta Pharmaceuticals; Shire
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics
  • Mechanism of Action Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Plaque psoriasis; Rheumatoid arthritis
  • Phase I Autoimmune disorders; Inflammation

Most Recent Events

  • 29 Nov 2016 Efficacy and adverse events data from a phase III trial in Plaque psoriasis released by Momenta
  • 11 Nov 2016 Immunogenicity and pharmacokinetics data from a phase I study in Healthy subjects presented at the 80th American College of Rheumatology and the 51st Annual Meeting of the Association of Rheumatology and Health Professionals (ACR/ARHP-2016)
  • 27 Sep 2016 Momenta Thearapeutics terminates its collaboration agreement with Shire for adalimumab biosimilar
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top